Seres Therapeutics, Inc. (MCRB) - 10-K Summary
Business Context and Reporting Period
Period: Fiscal year ended December 31, 2025.
Company Profile: Seres Therapeutics is a clinical-stage biopharmaceutical company developing live biotherapeutic products (LBPs) to treat infections and inflammatory/immune (I&I) diseases. In September 2024, the company sold its approved product, VOWST, to Nestlé Health Science (SPN). The company is now focused on its pipeline, primarily SER-155 (infection prevention in transplant patients) and SER-603 (inflammatory bowel disease).
Going Concern: Management has identified conditions raising substantial doubt about the company's ability to continue as a going concern for 12 months following the issuance of financial statements due to recurring losses and the need for additional funding.
Key Financial Metrics (Year Ended Dec 31, 2025)
| Metric | 2025 | 2024 |
|---|---|---|
| Total Revenue | $0.8 million (Grant revenue) | $0 |
| Operating Expenses | $94.8 million | $121.3 million |
| Loss from Operations | ($94.0 million) | ($121.3 million) |
| Net Income (Loss) from Continuing Ops | $5.7 million | ($125.8 million) |
| Cash and Cash Equivalents | $45.8 million | $30.8 million |
| Accumulated Deficit | ($972.4 million) | ($978.1 million) |
| Net Cash Provided by Operating Activities | $1.1 million | ($148.6 million) |
Note: The 2025 Net Income from Continuing Operations was driven by a $80.7 million gain on the sale of the VOWST Business (installment payments received from Nestlé). Operating cash flow was positive primarily due to these milestone payments.
Material Changes vs. Prior Period
- Revenue: Increased from $0 to $0.8 million due to a CARB-X grant awarded in Q3 2025.
- Operating Expenses: Decreased by $26.6 million (22%) year-over-year.
- R&D Expenses: Decreased $15.5 million to $49.1 million, driven by lower personnel costs (headcount reductions) and completion of the SER-155 Phase 1b study.
- G&A Expenses: Decreased $14.0 million to $39.2 million, primarily due to lower personnel costs and professional fees.
- Manufacturing Services: Increased $3.0 million to $6.5 million, reflecting a full year of transition services provided to Nestlé under the TSA.
- Other Income: Significant increase in "Gain on sale of VOWST Business" to $80.7 million in 2025 (vs. $5.7 million in 2024) due to the receipt of $75 million in installment payments from Nestlé.
- Headcount: Reduced from 66 employees at year-end 2025 to 45 employees by March 1, 2026, following cost-reduction actions in September 2025 and February 2026.
Guidance, Outlook, and Risks
Outlook & Strategy:
- Capital Needs: The company anticipates requiring additional funding following the third quarter of 2026. It is actively seeking partnerships or financing to advance SER-155 and other pipeline assets.
- Program Status:
- SER-155 (allo-HSCT): Phase 1b data showed a 77% relative risk reduction in bacterial bloodstream infections. The Phase 2 study protocol was submitted to the FDA in January 2026, but investment has been paused pending funding.
- SER-155 (irEC): An investigator-sponsored trial (IST) in immune checkpoint-related enterocolitis is fully enrolled; results expected in Q2 2026.
- SER-603 (IBD): Preclinical development ongoing for inflammatory bowel disease.
Key Risks & Contingencies:
- Going Concern: Substantial doubt exists regarding the ability to continue operations without additional financing. Failure to raise capital could lead to further cost reductions, program delays, or bankruptcy.
- Lease Obligations: The company has significant excess leased space ($118.4 million in future commitments) following the VOWST sale and workforce reduction, creating a fixed cost burden.
- Regulatory & Clinical: Risks associated with clinical trial enrollment, regulatory approval of novel live biotherapeutics, and the ability to secure funding for pivotal trials.
- Intellectual Property: Ongoing litigation regarding VOWST patents (Vedanta Biosciences/University of Tokyo) and potential challenges to patent validity.
Investor Verification Checklist
- Cash Runway: Verify the specific timeline for cash depletion and the status of ongoing fundraising efforts or partnership discussions.
- Lease Liability: Assess the company's plan to sublease or exit excess facility space to mitigate the $118.4 million in lease commitments.
- SER-155 Phase 2 Funding: Confirm if a partner or funding source has been secured to restart the paused Phase 2 study in allo-HSCT.
- Management Transition: Review the impact of the March 2026 leadership changes (Richard Kender as Interim CEO) on strategic execution.
- Grant Revenue: Monitor the utilization of the $3.6 million CARB-X grant for the liquid formulation of SER-155.